journal article·2026-02Open access

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

Wanrong Wang, Siqi Mu, Juan Zhang, Guisong Shan, Xueqian Li, Ran Wang, Tao Guo, Xiaoyan He

Advanced Science· Volume 13· Issue 10

Abstract

ABSTRACT Biomimetics is an interdisciplinary field that involves studying the structures, functions, principles, and behaviors of biological systems to draw inspiration and apply this knowledge to technological innovation and engineering design, thereby addressing complex challenges. ​​Biomimetic nanomedicine​​ represents a specific application of biomimetics within the realm of nanomedicine, where biological components are mimicked to construct sophisticated nanodrug delivery systems. These biomimetic nanosystems exhibit multiple unique advantages, including ​​targeted delivery to cells within the tumor microenvironment (TME)​​, ​​prolonged in vivo circulation time​​, ​​enhanced antigen/adjuvant loading capacity​​, and ​​high biocompatibility​​. These properties collectively ​​enhance the efficacy of chemotherapy, radiotherapy, immunotherapy, and photodynamic therapy (PDT)​​ by improving tumor‐specific targeting and reducing off‐target toxicity, thereby establishing biomimetic nanomedicines as ​​a promising platform for reprogramming the TME​​. This review highlights the ​​categorization​​, ​​design principles​​, and ​​manufacturing strategies​​ of biomimetic nanodrugs, providing a ​​systematic review​​ of the interplay between the TME and ​​biomimetic nanomedicines​​, and elucidating how their interaction potentiates tumor‐killing efficacy​​. Despite encouraging progress in biomimetic nanomedicines, challenges remain in their clinical translation, including biosafety concerns, scalable manufacturing processes, and optimal drug delivery efficiency. Advances in nanotechnology and precision engineering offer promising avenues for developing personalized biomimetic nanomedicines.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Research and Treatments · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Life Sciences Anhui Medical University Hefei P. R. China

Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Anhui Medical University Hefei P. R. China

Department of Endocrinology Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China

Department of Thyroid and Breast Surgery The First Affiliated Hospital of Anhui Medical University Anhui Public Health Clinical Center Hefei Anhui P. R. China

References (100+)

Show source-provided references
1. 10.1186/s12943-021-01316-810.1186/s12943-021-01316-8 ↗
2. 10.1093/annonc/mdw16810.1093/annonc/mdw168 ↗
3. 10.3390/pharmaceutics1507182110.3390/pharmaceutics15071821 ↗
4. 10.1038/s41573-021-00155-y10.1038/s41573-021-00155-y ↗
5. 10.1038/s41571-024-00959-y10.1038/s41571-024-00959-y ↗
6. 10.1016/j.semcancer.2019.09.00410.1016/j.semcancer.2019.09.004 ↗
7. 10.1186/s12943-023-01714-010.1186/s12943-023-01714-0 ↗
8. 10.1146/annurev-physiol-021119-03462710.1146/annurev-physiol-021119-034627 ↗
9. 10.1007/s11427-017-9178-y10.1007/s11427-017-9178-y ↗
10. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
11. 10.1021/acs.accounts.9b0055910.1021/acs.accounts.9b00559 ↗
12. 10.1007/s11010-019-03545-410.1007/s11010-019-03545-4 ↗
13. 10.1016/j.jconrel.2011.11.02110.1016/j.jconrel.2011.11.021 ↗
14. 10.1002/adma.20240507510.1002/adma.202405075 ↗
15. 10.1016/j.cis.2017.08.00510.1016/j.cis.2017.08.005 ↗
16. 10.1016/j.biomaterials.2017.02.04110.1016/j.biomaterials.2017.02.041 ↗
17. 10.2217/nnm-2017-022510.2217/nnm-2017-0225 ↗
18. 10.1038/s41419-020-03221-210.1038/s41419-020-03221-2 ↗
19. 10.1038/s41568-021-00339-z10.1038/s41568-021-00339-z ↗
20. 10.1038/s41571-024-00859-110.1038/s41571-024-00859-1 ↗
21. 10.3389/fimmu.2024.148272810.3389/fimmu.2024.1482728 ↗
22. 10.1038/s41423-021-00741-510.1038/s41423-021-00741-5 ↗
23. 10.1016/j.coi.2019.04.00310.1016/j.coi.2019.04.003 ↗
24. 10.1016/j.ccell.2016.06.00310.1016/j.ccell.2016.06.003 ↗
25. 10.1126/scitranslmed.aav743110.1126/scitranslmed.aav7431 ↗
26. 10.1016/j.celrep.2024.11486810.1016/j.celrep.2024.114868 ↗
27. 10.1016/j.celrep.2015.11.05310.1016/j.celrep.2015.11.053 ↗
28. 10.1158/2159-8290.CD-19-007410.1158/2159-8290.CD-19-0074 ↗
29. 10.3390/cancers1321531810.3390/cancers13215318 ↗
30. 10.1038/s41392-021-00506-610.1038/s41392-021-00506-6 ↗
31. 10.3390/ijms2213699510.3390/ijms22136995 ↗
32. 10.1172/JCI12864410.1172/JCI128644 ↗
33. 10.1038/nature1203410.1038/nature12034 ↗
34. 10.1016/j.mam.2011.04.00510.1016/j.mam.2011.04.005 ↗
35. 10.1002/jcp.2642910.1002/jcp.26429 ↗
36. 10.1016/j.canlet.2024.21707610.1016/j.canlet.2024.217076 ↗
37. 10.1038/s41590-024-01896-910.1038/s41590-024-01896-9 ↗
38. 10.1038/s41416-020-01048-410.1038/s41416-020-01048-4 ↗
39. 10.1016/j.canlet.2022.21604310.1016/j.canlet.2022.216043 ↗
40. 10.3389/fimmu.2018.0001410.3389/fimmu.2018.00014 ↗
41. 10.3389/fimmu.2023.127123610.3389/fimmu.2023.1271236 ↗
42. 10.1038/s41577-021-00574-310.1038/s41577-021-00574-3 ↗
43. 10.1126/science.aaa620410.1126/science.aaa6204 ↗
44. 10.3389/fimmu.2020.0006010.3389/fimmu.2020.00060 ↗
45. 10.1038/s41571-020-0426-710.1038/s41571-020-0426-7 ↗
46. 10.1002/JLB.MR0718-269R10.1002/JLB.MR0718-269R ↗
47. 10.3389/fimmu.2019.0120510.3389/fimmu.2019.01205 ↗
48. 10.3389/fimmu.2021.68338110.3389/fimmu.2021.683381 ↗
49. 10.1084/jem.2018145410.1084/jem.20181454 ↗
50. 10.1016/j.ccell.2018.03.01210.1016/j.ccell.2018.03.012 ↗
51. 10.1038/s41571-019-0175-710.1038/s41571-019-0175-7 ↗
52. 10.1016/j.canlet.2020.07.02210.1016/j.canlet.2020.07.022 ↗
53. 10.1186/s12943-020-01234-110.1186/s12943-020-01234-1 ↗
54. 10.3390/ijms2513734610.3390/ijms25137346 ↗
55. 10.1126/science.120294710.1126/science.1202947 ↗
56. 10.1016/j.trecan.2022.06.00810.1016/j.trecan.2022.06.008 ↗
57. 10.1002/cac2.1234510.1002/cac2.12345 ↗
58. 10.1038/s41423-023-01061-610.1038/s41423-023-01061-6 ↗
59. 10.4049/jimmunol.176.8.502310.4049/jimmunol.176.8.5023 ↗
60. 10.1186/s12943-019-0976-410.1186/s12943-019-0976-4 ↗
61. 10.3389/fimmu.2023.129525710.3389/fimmu.2023.1295257 ↗
62. 10.1186/s12943-022-01657-y10.1186/s12943-022-01657-y ↗
63. 10.1084/jem.2013191610.1084/jem.20131916 ↗
64. 10.4049/jimmunol.150095910.4049/jimmunol.1500959 ↗
65. 10.3390/ijms1912380510.3390/ijms19123805 ↗
66. 10.3390/cells1102031010.3390/cells11020310 ↗
67. 10.1038/s41392-021-00670-910.1038/s41392-021-00670-9 ↗
68. 10.1016/j.gendis.2022.10.00610.1016/j.gendis.2022.10.006 ↗
69. 10.3390/cancers1211324410.3390/cancers12113244 ↗
70. 10.1158/2326-6066.CIR-18-048110.1158/2326-6066.CIR-18-0481 ↗
71. 10.1080/15384101.2018.144430510.1080/15384101.2018.1444305 ↗
72. 10.3389/fonc.2018.0008110.3389/fonc.2018.00081 ↗
73. 10.1002/advs.20210099710.1002/advs.202100997 ↗
74. 10.1016/j.celrep.2015.08.07710.1016/j.celrep.2015.08.077 ↗
75. 10.1016/j.biochi.2021.01.00510.1016/j.biochi.2021.01.005 ↗
76. 10.1016/j.tips.2017.11.00710.1016/j.tips.2017.11.007 ↗
77. 10.1016/j.semcancer.2021.10.00210.1016/j.semcancer.2021.10.002 ↗
78. 10.18632/oncotarget.1240910.18632/oncotarget.12409 ↗
79. 10.1172/JCI15983910.1172/JCI159839 ↗
80. 10.1073/pnas.091443310710.1073/pnas.0914433107 ↗
81. Inhibition of HIF‐1α by PX‐478 Suppresses Tumor Growth of Esophageal Squamous Cell Cancer in Vitro and in Vivo
82. 10.2147/IJN.S44113510.2147/IJN.S441135 ↗
83. 10.3390/ijms2215810210.3390/ijms22158102 ↗
84. 10.1038/s41374-021-00699-y10.1038/s41374-021-00699-y ↗
85. 10.1158/1535-7163.MCT-18-122510.1158/1535-7163.MCT-18-1225 ↗
86. 10.1083/jcb.20190306610.1083/jcb.201903066 ↗
87. 10.1007/s00018-019-03351-710.1007/s00018-019-03351-7 ↗
88. 10.3389/fimmu.2018.0052710.3389/fimmu.2018.00527 ↗
89. 10.1016/j.it.2016.01.00410.1016/j.it.2016.01.004 ↗
90. 10.1007/s10456-014-9420-y10.1007/s10456-014-9420-y ↗
91. 10.3390/ijms2207376510.3390/ijms22073765 ↗
92. 10.1016/j.ejpb.2015.03.01810.1016/j.ejpb.2015.03.018 ↗
93. 10.3390/cells704002410.3390/cells7040024 ↗
94. 10.1146/annurev-immunol-032713-12014210.1146/annurev-immunol-032713-120142 ↗
95. 10.1007/s10555-020-09898-310.1007/s10555-020-09898-3 ↗
96. 10.1002/smll.20200648410.1002/smll.202006484 ↗
97. 10.1016/j.actbio.2020.05.02810.1016/j.actbio.2020.05.028 ↗
98. 10.1016/j.apsb.2023.03.00410.1016/j.apsb.2023.03.004 ↗
99. 10.1016/j.apsb.2019.01.01110.1016/j.apsb.2019.01.011 ↗
100. The Loading of human Erythrocytes with Small Molecules by Electroporation